Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Buoyed by strong performance of its key brands Januvia (sitagliptin) and Gardasil launched last year in India, U.S. drug giant Merck is going full throttle in its ambition to figure in the top five companies in India by 2015
You may also be interested in...
A Closer Look At Merck's Commercial Restructuring: What Happened To India?
In the latest overhaul of its commercial operations, Merck shared enthusiasm about prospects in emerging markets. But it did not include India, Turkey and Poland in its list of top 10 priority markets, a change from its vision shared just four years ago
As Tough Market And Policy Challenges Loom, J&J Names New India Leadership For Pharma Business
With former MSD hand Sanjiv Navangul as its new India CEO, experts believe J&J will make deeper inroads in the country. The new leader will be expected to make his way through regulatory bottlenecks at home while convincing global leadership to launch new drugs quickly for the Indian market.
Emerging Markets Earnings Roundup: Bayer And Merck (Part 3)
Emerging markets were a mixed picture for Big Pharma in the third quarter, with China the clear leader, but overall key markets continued to see slower growth, which many blamed on the slowdown in the West.